Lana Pine

Various factors related to demographics, psychosocial behavior variables, and clinical characteristics were linked to health-related quality of life in patients with gout.

Among the fibromyalgia studies conducted in the US and Canada over the past 22 years, 90% of participants identified as White.

The progression toward more targeted, disease-modifying options for the historically difficult rheumatic disease made more headway in 2023.

Stacie Bell, PhD, emphasizes the importance of collaborative or multidisciplinary care in patients with SLE.

Stacie Bell, PhD, highlights the lasting effects of childhood adversities in patients with pediatric lupus.

Stacie Bell, PhD, discusses the disagreement between adolescents and parents regarding how lupus impacts daily life.

Data from the phase 3 TULIP long-term extension trial support the favorable benefit-risk profile of anifrolumab-fnia demonstrated in previous trials.

Results provide the first clinical evidence to suggest that afimetoran may offer a benefit to patients with cutaneous lupus erythematosus.

Results showed treatment with dipeptidyl peptidase-4 inhibitors (DPP-4i) improved bone mineral density and reduced osteoporosis risk in patients with type 2 diabetes.

Findings provide a theoretical framework for the early diagnosis and treatment of heart disease in patients with gout, especially for older individuals and those with hypertension.

Laura Donlin, PhD, highlights the significance of identifying new subtypes of rheumatoid arthritis, emphasizing the potential for a paradigm shift in RA treatment toward personalized care and early interventions.

Patients with gout who did not experience recurrent flares had a shorter mean time between diagnosis and the start of urate-lowering therapy compared with those who had ≥1 flare.

Patients with gout achieving target serum uric acid levels showed good adherence to urate-lowering therapy, used antihypertensive agents, and lacked a family history of gout.

Waist circumference and high lipid levels were associated with poor disease outcomes in gout, including flares and failure to achieve treatment target.

Patients with the highest Dietary Inflammatory Index have an increased risk of gout.

Peter C Taylor, PhD, discusses the efficacy and safety of nipocalimab in patients with active rheumatoid arthritis.

SIRI emerged as a significant factor influencing acute gout attacks, shedding light on a prospective diagnostic tool.

Approximately one third of patients with temporomandibular disorders had comorbid fibromyalgia.

Results of a database search reveal the management of pain symptoms remains a continued source of frustration and an unmet need for patients with fibromyalgia.

In the November 2023 rheumatology month in review, our editorial team highlights ACR conference coverage, the latest updates in fibromyalgia, and advancements in patient care.

At 12 weeks, significantly more patients with fibromyalgia receiving the smartphone-based intervention reported clinical improvements compared with the control group.

Findings may be related to a variety of influences including a slower life pace during the pandemic and resilience to prolonged stressors.

Common themes included preferring a standard list of symptoms, active training programs, and the desire for community.

Patients with juvenile onset fibromyalgia and joint hypermobility demonstrated poorer overall functioning compared with those without joint hypermobility.

A clinically significant percentage of patients with fibromyalgia in the immediate intervention group had greater improvements in quality of life compared with patients in the delayed cohort.

Fibromyalgia was 3 times more common among patients with rheumatoid arthritis and Long COVID.

As fibromyalgia impact increased, self-stigmatization scores increased proportionally.

Results demonstrated rumination induction after physical activity stunted patients’ recovery regarding discomfort and pain intensity compared with patients using a distraction method.

John Botson, MD, discusses his study examining real-world pegloticase plus immunomodulation co-therapy using data from an insurance claims database.

At month 6, more patients in the AR882 75 mg cohort demonstrated complete resolution of ≥1 tophus compared with patients in the allopurinol cohort.